Therefore, inhibition of these proinflammatory cytokines has become a strategy for the treatment of RA, and then corresponding biological agents such as anti-TNF-α (adalimumab), anti-IL-1 (anakinra), and anti-IL-6 (tocilizumab) have been applied in the treatment of RA in clinical settings [19–21]. The gene discussed is IL1B; the disease is rheumatoid arthritis.